Company Encyclopedia
View More
name
4D Molecular Therapeutics
FDMT.US
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc.
1.876 T
FDMT.USMarket value -Rank by Market Cap -/-

Financial Score

14/11/2025 Update
C
BiotechnologyIndustry
Industry Ranking115/389
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-45.38%E
    • Profit Margin-174314.17%E
    • Gross Margin-52386.67%E
  • Growth ScoreB
    • Revenue YoY605.88%A
    • Net Profit YoY-45.79%D
    • Total Assets YoY-29.81%E
    • Net Assets YoY-33.27%E
  • Cash ScoreB
    • Cash Flow Margin-0.06%D
    • OCF YoY605.88%A
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreA
    • Gearing Ratio12.97%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    4D Molecular Therapeutics (NASDAQ:FDMT) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

    4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly earnings of ($1.01) EPS, beating estimates of ($1.02) by $0.01. The company had revenue of $0.09 million, below the expected $0.40 million. Despite a negative return on equity of 40.15% and a net margin of 594,375.81%, the stock rose to $10.80. Analysts have mixed ratings, with a consensus of "Moderate Buy" and an average price target of $28.70. Recent insider selling and significant institutional ownership were noted, with 99.27% of shares held by institutional investors.

    Market Beat·
    US
    FDMT
    +4.86%
    Market Beat·
    US
    FDMT
    +4.86%

    Promising Outlook for 4D Molecular Therapeutics: Buy Rating Backed by Strategic Partnerships and Strong Financial Position

    4D Molecular Therapeutics received a Buy rating from analyst Matthew Caufield of H.C. Wainwright, with a price target of $36.00. The rating is supported by positive data from the Phase 1/2 PRISM trial of its gene therapy candidate, 4D-150, and a strategic partnership with Otsuka Pharmaceutical, which provided $85 million upfront. The company also secured an $11 million investment from the CF Foundation and completed a $93 million equity offering, ensuring a strong financial position to support its pipeline.

    Tip Ranks·
    US
    FDMT
    +4.86%
    Tip Ranks·
    US
    FDMT
    +4.86%

    Morgan Stanley Reaffirms Their Hold Rating on 4D Molecular Therapeutics (FDMT)

    Morgan Stanley analyst Judah Frommer has reaffirmed a Hold rating on 4D Molecular Therapeutics (FDMT), with shares closing at $10.17. The analyst consensus for the stock is Strong Buy, with a price target of $34.43, indicating a potential upside of 238.54%. Another report from TR | OpenAI also maintained a Hold rating with a price target of $10.50. Frommer has an average return of 0.9% and a 55.02% success rate on his stock recommendations.

    Tip Ranks·
    US
    FDMT
    +4.86%
    Tip Ranks·
    US
    FDMT
    +4.86%

    Chardan Capital Sticks to Its Buy Rating for 4D Molecular Therapeutics (FDMT)

    Chardan Capital has maintained a Buy rating on 4D Molecular Therapeutics (FDMT) with a price target of $26.00, according to analyst Geulah Livshits. Livshits, a 5-star analyst, has an average return of 22.2% and a 41.55% success rate. Other analysts, including Evercore ISI's Jonathan Miller, also rated FDMT as a Buy, while Morgan Stanley upgraded it to a Hold on November 6.

    Tip Ranks·
    US
    FDMT
    +4.86%
    Tip Ranks·
    US
    FDMT
    +4.86%

    4D Molecular Therapeutics | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 90 K

    LB filings·
    US
    FDMT
    +4.86%
    LB filings·
    US
    FDMT
    +4.86%